PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PCLOK II HBsAg/HIV p24. In addition, the company offers platform services, such as SG ID for identifying novel target substances. Further, it offers covid-19 solutions, such as PCLMD nCoV one step RT-PCR, PCL COVID19 speed RTPCR, PCLMD ABC multi RTPCR molecular diagnostic kits; PCL COVID19 Ag rapid FIA, and PCL COVID19 Ag gold antigen diagnostic kits; and PCL COVID19 IgG/IgM rapid gold, and PCL COVID19 total Ab EIA antibody diagnostic kits. PCL, Inc. was incorporated in 2008 and is headquartered in Seoul, South Korea.
तुलना करने के लिए मीट्रिक्स | 241820 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध241820पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.4x | −2.8x | −0.5x | |
PEG अनुपात | 0.00 | 0.01 | 0.00 | |
क़ीमत/बुक | 6.2x | 1.5x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 3.4x | 4.3x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 51.7% | 50.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 1.1% | 7.7% | अनलॉक करें |